Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clofarabine - Sanofi

X
Drug Profile

Clofarabine - Sanofi

Alternative Names: CAFdA; Cl-F-ara-A; Clofaribine; Clolar; Evoltra; GZ393590; JC0707; SAR 393590

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Southern Research Institute
  • Developer Bioenvision; Dana-Farber Cancer Institute; Erasmus MC; Genzyme Oncology; Massachusetts General Hospital; Oncology Specialists S.C.; Sanofi; Sanofi Oncology; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospital Southampton NHS Foundation Trust; University of California; University of Michigan Comprehensive Cancer Center; University of Utah; Yale University
  • Class Antineoplastics; Antipsoriatics; Furans; Purine nucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Histiocytosis
  • Phase I/II Haematological malignancies
  • Preregistration Submission Withdrawal Acute myeloid leukaemia
  • Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Psoriasis; Solid tumours

Most Recent Events

  • 13 Mar 2023 Massachusetts General Hospital completes a phase I/II trial in Non-Hodgkin's lymphoma (Second line therapy or greater) in the USA (PO) (NCT00644189)
  • 27 Jul 2020 University of California in collaboration with Genzyme Sanofi terminates a phase-I/II clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (In adolescents, In children, In adults, Combination therapy, Second-line therapy or greater) in USA (IV), prior to July 2020 (NCT00983528)
  • 28 Feb 2019 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(In children) in Unknown (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top